Astorg Partners, a private equity firm, completed the acquisition of CordenPharma, a pharmaceutical CDMO, from International Chemical Investors Group, a chemical company, for $3.2bn. "The transaction is the result of our thematic sourcing effort in pharma services. We identified the Company as a leading CDMO focused on some of the most promising areas of pharma R&D and with a strong customer focus and unique innovation capabilities," Judith Charpentier, Astorg Partner and Head of Healthcare.